U.S. Markets open in 6 hrs 20 mins

Santhera Pharmaceuticals Holding AG (SANN.SW)


Swiss - Swiss Delayed Price. Currency in CHF
Add to watchlist
61.90-2.90 (-4.48%)
As of 5:30PM CEST. Market open.
Interactive chart
Previous Close64.80
Open64.40
Bid62.50 x
Ask60.95 x
Day's Range61.20 - 65.80
52 Week Range37.05 - 86.35
Volume91,937
Avg. Volume34,614
Market Cap388.5M
Beta3.06
PE Ratio (TTM)-10.96
EPS (TTM)N/A
Earnings DateN/A
Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
  • TheStreet.com2 years ago

    Santhera Drug Wins European Approval for Rare Blindness Disease

    The Santhera drug, Raxone, is the first approved treatment for Leber hereditary optic neuropathy (LHON), which affects approximately 10,000 patients in Europe.

  • TheStreet.com2 years ago

    Santhera Drug Win European Approval for Rare Blindness Disease

    The Santhera drug, Raxone, is the first approved treatment for Leber hereditary optic neuropathy (LHON), which affects approximately 10,000 patients (mostly males) in Europe.

  • Reuters2 years ago

    Europe gives green light to new Novartis, Alexion drugs

    New drugs from Novartis and Alexion won a green light from European regulators on Friday, delivering a boost to both drugmakers and offering new treatment options for cancer and rare diseases. Experts from the European Medicines Agency (EMA) said they had recommended approval of Novartis's Farydak for multiple myeloma, an aggressive blood cancer, and Odomzo for basal cell carcinoma, a type of skin cancer.